C3 Cannabinoids

C3 Cannabinoid Compound Company is a prominent European pharmaceutical firm dedicated to the development, production, and marketing of cannabinoid-based medicinal products. Established in 2014 as a spin-off from Bionorica SE, the company is a market leader in the production of dronabinol, a standardized pharmaceutical-grade tetrahydrocannabinol (THC). Its products are primarily utilized in the fields of pain management, oncology, and palliative care to treat symptoms such as chronic pain and chemotherapy-induced nausea. In 2019, the company was acquired by Canopy Growth Corporation for approximately $250 million to expand its medical cannabis footprint in the European market.